The Evolving Melanoma Landscape and Identifying the Right Candidate

This segment examines how far advanced melanoma treatment has come and where meaningful gaps remain. The faculty trace the progress made through checkpoint inhibitors while acknowledging that a substantial portion of patients still develop primary or acquired resistance and need additional options. The discussion explores where cellular therapy now fits, positioning it as a chance at long-term remission for eligible patients rather than a treatment of last resort. A central theme is candidate selection: the experts detail the practical factors that determine eligibility, including the need for an accessible, appropriately sized tumor for procurement and sufficient patient fitness to withstand a demanding process. They also address the importance of anticipating how a patient's disease may progress during the manufacturing window, and how thoughtful sequencing, particularly around mutation status, can preserve the opportunity for this therapy rather than allowing the disease to dictate the timeline.